{"id":"lumateperone-iti-007","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Orthostatic hypotension"},{"rate":"10-20%","effect":"Weight gain"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lumateperone acts as a partial agonist at the serotonin 5-HT2A receptor and a dopamine D2 receptor antagonist. This mechanism of action is thought to contribute to its therapeutic effects in treating schizophrenia and bipolar depression.","oneSentence":"Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:46.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar depression"}]},"trialDetails":[{"nctId":"NCT02600494","phase":"PHASE3","title":"Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-12-15","conditions":"Bipolar Depression","enrollment":554},{"nctId":"NCT01499563","phase":"PHASE2","title":"Study of a Novel Antipsychotic ITI-007 in Schizophrenia","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2011-12","conditions":"Schizophrenia","enrollment":335},{"nctId":"NCT02282761","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2014-11","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT02469155","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-06","conditions":"Schizophrenia","enrollment":696},{"nctId":"NCT02600507","phase":"PHASE3","title":"Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2016-03-07","conditions":"Bipolar Depression","enrollment":529},{"nctId":"NCT03249376","phase":"PHASE3","title":"Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2017-11-27","conditions":"Bipolar Depression","enrollment":381},{"nctId":"NCT03817528","phase":"PHASE2","title":"ITI-007 (Lumateperone Tosylate) for Schizophrenia","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-03-01","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT02817906","phase":"PHASE3","title":"ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease","status":"TERMINATED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2016-08-29","conditions":"Agitation in Dementia, Including Alzheimer's Disease","enrollment":177},{"nctId":"NCT02078310","phase":"PHASE1, PHASE2","title":"Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2014-02","conditions":"Alzheimer's Disease","enrollment":35},{"nctId":"NCT02288845","phase":"PHASE2","title":"Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2014-10","conditions":"Schizophrenia","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lumateperone (ITI-007)","genericName":"Lumateperone (ITI-007)","companyName":"Intra-Cellular Therapies, Inc.","companyId":"intra-cellular-therapies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lumateperone is a serotonin-dopamine antagonist that modulates glutamatergic neurotransmission. Used for Schizophrenia, Bipolar depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}